# Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

> **NCT00242710** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 1083 (actual)

## Conditions studied

- Endometrial Hyperplasia
- Osteoporosis

## Interventions

- **DRUG:** Bazedoxifene/Conjugated Estrogen
- **DRUG:** Bazedoxifene/Conjugated Estrogen
- **DRUG:** CE 0.45 mg/MPA 1.5mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00242710
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 1083 (ACTUAL)
- **Last updated:** 2013-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00242710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00242710, "Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00242710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*